Skip to main content

Steglatro News

Sodium-Glucose Cotransporter 2 Inhibitors Increase Risk for Falls in Patients With Diabetes

WEDNESDAY, April 30, 2025 – Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent risk factor for falls in people with type 2 diabetes, according to a study published online March...

Some Diabetes Meds Could Lower Odds for Dementia, Parkinson's

THURSDAY, Sept. 19, 2024 – A specific class of diabetes drug appears to lower people’s risk for dementia and Parkinson’s disease, a new study shows. Sodium-glucose cotransporter-2 (SGLT2) inh...

FDA Medwatch Alert: SGLT2 (sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

ISSUE: FDA is warning that cases of a rare but serious infection of the genitals and area around the genitals have been reported with the class of type 2 diabetes medicines called sodium-glucose...

FDA Approves Segluromet (ertugliflozin and metformin hydrochloride) for Type 2 Diabetes

KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE) December 22, 2017 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food...

FDA Approves Steglujan (ertugliflozin and sitagliptin) for Type 2 Diabetes

KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE) December 22, 2017 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food...

FDA Approves Steglatro (ertugliflozin) for Type 2 Diabetes

KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE) December 22, 2017 – Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced that the U.S. Food...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Diabetes, Type 2

Steglatro patient information at Drugs.com